RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, Kiyota M, Nakayama R, Mizutani S, Chinen Y, Sakamoto N, Matsumoto Y, Horiike S, Shiotsu Y, Iida S, Taniwaki M.
Shimura Y, et al. Among authors: mizutani s.
Mol Cancer Ther. 2012 Dec;11(12):2600-9. doi: 10.1158/1535-7163.MCT-12-0605. Epub 2012 Sep 25.
Mol Cancer Ther. 2012.
PMID: 23012246